SCHEMBL3068370

SCHEMBL3068370

O=C(c1nc2c(C(F)(F)F)cc(-c3ccco3)cn2c1Cl)N1CCC(N2CCOC2=O)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RBP4 P02753 3/20 0.36
F10 P00742 1/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 5/20 0.34
TSHR P16473 3/20 0.34
HPGD P15428 3/20 0.34
CASP1 P29466 3/20 0.34
CASP7 P55210 3/20 0.34
HSD17B10 Q99714 3/20 0.34
SCD5 Q86SK9 2/20 0.34
VNN1 O95497 1/20 0.34
LMNA P02545 2/20 0.33
P2RX7 Q99572 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HTT P42858 2/20 0.33
TRPV1 Q8NER1 1/20 0.33
CYP1A2 P05177 1/20 0.33
KDM4E B2RXH2 2/20 0.33
USP2 O75604 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3053754 0.89 SCD5 (0.39) RBP4F10SCD5VNN1TRPV1
SCHEMBL3057958 0.87 VNN1 (0.35) F10RAB9ANPC1ALDH1A1TSHR
SCHEMBL3057907 0.87 F10 (0.36) RBP4F10SCD5VNN1TRPV1
SCHEMBL3071150 0.86 F10 (0.36) RBP4F10SCD5VNN1P2RX7
SCHEMBL3071106 0.86 HSD11B1 (0.39) RBP4F10RAB9AALDH1A1TSHR
SCHEMBL3053749 0.86 F10 (0.36) RBP4F10ALDH1A1CASP1CASP7
SCHEMBL3058415 0.86 PIK3CA (0.36) RBP4F10RAB9ANPC1ALDH1A1
SCHEMBL3057911 0.86 NPY5R (0.40) RBP4F10ALDH1A1SCD5VNN1
SCHEMBL3066363 0.86 RBP4 (0.36) RBP4F10RAB9ANPC1ALDH1A1
SCHEMBL3074557 0.85 F10 (0.36) RBP4F10SCD5VNN1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents BASKARAN SUBRAMANIAN 2010-10-28 US claimed
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents BASKARAN SUBRAMANIAN 2010-10-28 US disclosed
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents BASKARAN SUBRAMANIAN 2010-10-28 US disclosed
WO-2010091411-A1 PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2010-08-12 WO disclosed
WO-2010091411-A1 PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents ZC3HAV1, MAVS, EIF2AK2 RBP4 2908/4885F10 2944/4885RAB9A 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.